Atopic Dermatitis Therapy Landscape.

What is the landscape of advanced systemic therapies for moderate-to-severe atopic dermatitis in the United States and Europe, for an immunology franchise planning its access strategy?

The guidelines draw the boundary between systemic therapy classes. The landscape uses them to define the market and the segments, and marks where the American and European guidelines differ.

Segments from the guidelines. The landscape groups therapies by class using the guidelines, so the segments are those clinicians use and not ones the landscape invents. A product that sits between classes is listed once, under its primary class.^{1Davis, D. M. R. et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology, 2023.,2Wollenberg, A. et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. Journal of the European Academy of Dermatology and Venereology, 2022;36(9):1409–1431.}

Two guidelines, two systems. The American guideline grades recommendations with GRADE and the European one is a consensus guideline developed over four conferences for non-systemic care and a separate first part for systemic care. The landscape shows where they differ and does not merge them.^{1Davis, D. M. R. et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology, 2023.,2Wollenberg, A. et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. Journal of the European Academy of Dermatology and Venereology, 2022;36(9):1409–1431.}

Access is part of the map. A product’s position depends on how national bodies have assessed it. The landscape lists published decisions for the main markets and marks those it could not find.^{4Gemeinsamer Bundesausschuss (Federal Joint Committee). Benefit assessment of medicinal products. English page.}

What is shaping it. At Comprehensive length the landscape names the forces: new entrants in the pipeline, guideline updates, payer assessment, and the move from older immunosuppressants.^{3U.S. National Library of Medicine, ClinicalTrials.gov; European Medicines Agency, Clinical Trials Information System (CTIS) public site.}

The landscape states the assumptions its boundary and its sizes rest on, and says what each gap limits. Examples for this market:

• The guidelines cited are the current versions in each region.
• Registered trials capture the pipeline that matters.
• Published national decisions capture how the products are assessed.

The decision practice behind the memo itself is on the template page.

Any product whose class the guidelines do not settle, any pipeline program known from only one register, and any market size that comes from a vendor report.

1. The picture in brief
2. Scope and boundary
3. The market in numbers
4. Who plays where
5. What is shaping it
6. What it means for us
7. What we could not source

1. [1] Davis, D. M. R. et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology, 2023. Recommendations as reported in trade and news summaries found by search; the guideline was not read in full.
2. [2] Wollenberg, A. et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. Journal of the European Academy of Dermatology and Venereology, 2022;36(9):1409–1431. Known from repository records; the recommendations were not read.
3. [3] U.S. National Library of Medicine, ClinicalTrials.gov; European Medicines Agency, Clinical Trials Information System (CTIS) public site. Search on a stated date; results change.
4. [4] Gemeinsamer Bundesausschuss (Federal Joint Committee). Benefit assessment of medicinal products. English page. Read in full on 9 October 2026.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.